FDA 483 - Ajinomoto Althea, Inc. - March 18, 2019

An FDA inspection of Ajinomoto Althea, Inc. in San Diego, CA, a drug manufacturer, revealed three observations. The firm was cited for inadequate deviation investigations regarding broken vials, a lack of quality control unit oversight due to an unclear quality agreement, and a failure to perform required clean hold time studies and cleaning validation.